View Archive

Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the ACCME to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Merck & Co., Inc., and Exelixis, Inc.

ASCO GU: How Will You Sequence Now? Personalizing Care Along the RCC Treatment Continuum When There are Many Options

ASCO GU: How Will You Sequence Now? Personalizing Care Along the RCC Treatment Continuum When There are Many Options

February 14, 2020

Dinner/Registration: 6:15 PM – 6:45 PM
Program: 6:45 PM – 8:45 PM

San Francisco Marriott Marquis
Yerba Buena Ballroom, Salon 9
780 Mission St
San Francisco, CA 94103

Personalizing Care Along the RCC Treatment Continuum Overview

The CME-certified activity, How Will You Sequence Now? Personalizing Care Along the RCC Treatment Continuum When There are Many Options, is an interactive, live educational symposium to be held adjunct to the 2019 Genitourinary Cancers Symposium in San Francisco. The availability of new systemic immune checkpoint inhibitor (ICI) and vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) agents and combination regimens (eg, ICI-ICI, ICI-TKI) has expanded the lines of therapy available to your patients with metastatic renal cell carcinoma (mRCC). Consequently, new clinical dilemmas regarding rational treatment planning and optimized sequencing of new and older standards of care have arisen.

Known for its engaging format, this panel discussion−based program features a review of the most recent and practically relevant data and best practices, along with spirited debates between faculty and attendees regarding clinical uncertainties faced in daily practice. For example: What factors should influence your frontline and subsequent-line treatment selection? Is there still a role for IMDC risk stratification? How should you monitor and manage toxicities associated with newer regimens? What are the evolving roles of local therapy in the modern era? Are additional practice changes anticipated to arise in 2020?

Please join us for this dynamic educational activity designed to help you apply evidence-based, state-of-the-art management strategies to your practice.

Benefits of Participating in This Live CME Event, Hosted by PER®

  • Hear from the experts on how they approach RCC cases you typically encounter in your clinical practice
  • Improve your ability to optimize clinical decision making for your patients with advanced/metastatic RCC
  • Compare your practices with those of the experts and your colleagues

Acknowledgement of Commercial Support

This activity is supported by educational grants from Merck & Co., Inc., and Exelixis, Inc.

Target Audience: HCPs Who Treat Renal Cell Carcinoma

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of RCC. Urologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with RCC are also invited to participate.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the biologic rationale for the use of targeted agents and immunotherapies, as single agents and in combination, to treat RCC.
  • Analyze practice-changing and emerging data from clinical trials of systemic therapies for use across multiple lines of therapy for advanced RCC.
  • Integrate knowledge of the safety profiles of systemic therapies with best practices to proactively identify and mitigate treatment-related toxicities during treatment planning for patients with metastatic RCC.
  • Consider the efficacy and safety of single-agent and combination systemic therapies, as well as patient and disease characteristics and patient preferences, as part of shared decision making for patients with metastatic RCC.

Program Chair

Robert A. Figlin
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Associate Director, Oncology Service Line, Cedars-Sinai Cancer
Cedars-Sinai Medical Center
Los Angeles, CA


2 Ways to Register
  1. Online: Click here.
  2. Phone: Please call +1-(888)-949-0045 or +1-(609)-378-3701.
Physicians' Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By